



ORIGINAL ARTICLE

Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial

Neda Ashayeri, Elham Sadeghi, Sara Sadeghi, Peyman Eshghi, Samin Alavi

Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article History:

Received: 26.08.2016

Accepted: 19.10.2016

Keywords:

Beta-thalassemia major

Oral iron chelators

Deferasirox

Iron overload

Heart MRI T2*

Liver MRI T2*

*Corresponding author:

Samin Alavi, MD

Address: Pediatric Congenital

Hematologic Disorders Research

Center, Shahid Beheshti University of

Medical Sciences, Tehran, Iran

Tel: +98 21 22227020

Fax: +98 21 22220254

Email: S.alavi@sbmu.ac.ir

ABSTRACT

Background: Iron chelators are an important part of management of patients with thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron overload in these patients who receive regular blood transfusion. We aimed to compare the efficacy and safety of available oral iron chelator; Deferasirox (Exjade®) with Deferasirox (Osveral®) in reducing iron overload in patients with β -thalassemia major.

Methods: Children suffering from β -thalassemia major referring to Mofid Children Hospital were enrolled in this non-randomized clinical trial. The patients were divided into two groups receiving Deferasirox (Exjade®) versus Deferasirox (Osveral®) and their response to either treatment was assessed by measurement of serum ferritin levels and estimation of cardiac and liver iron by MRI T2* of heart and liver. Efficacy of either medication was compared before and after 12 months of treatment. Serum ferritin levels were measured every three months. Mean serum ferritin at baseline was compared with post-treatment values. MRI T2* of heart and liver was performed before and after treatment.

Results: Out of 69 patients with a mean age of 13.6 ± 7.4 years, 42 (60.9%) were male. 30 patients were assigned to take Deferasirox (Exjade®) and 39 patients to take Deferasirox (Osveral®). The groups were not different regarding the age and the gender ($P=0.18$ and 0.621 , respectively). There was no statistically significant difference in post-treatment serum ferritin level measurements between the two groups. In patients who received Osveral®, decrease in liver iron overload was significant (0.99 ms in Exjade® group vs 1.16 ms in Osveral® group, $p=0.007$). In the group of patients who received Exjade®, decrease in cardiac iron overload was significant (4.52 in Exjade group vs 1.71 in Osveral group, $P<0.001$).

Conclusion: Deferasirox (Osveral®), the iron chelator manufactured in Iran, was as efficient as Deferasirox (Exjade®) in iron removal and could be a substitute for Deferasirox (Exjade®).

Please cite this article as: Ashayeri N, Sadeghi E, Sadeghi S, Eshghi P, Alavi S. Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial. IJBC 2016; 8(4): 103-107.

Introduction

β -thalassemia is the most frequent hereditary anemia with a high prevalence in many countries.^{1,2} It is considered the most common hereditary disease in Iran with approximately 26000 thalassemia major patients and three million carriers in the country.³ This disease is

associated with a high rate of morbidity and mortality; it induces anemia, splenomegaly, bone marrow expansion and bone deformities and requires life-long blood transfusion leading to iron accumulation and ultimately organ damage.^{4,5}

Due to the fatal effect of iron accumulation in patients

suffering from β -thalassemia major,⁶ treatment with iron chelators is necessary for longer survival. Deferoxamine; a hexadentate, has been used since 1960s as the standard iron chelator and has been established to prolong survival of the patients with beta thalassemia major and decrease morbidity and mortality of the patients, but during the last decade its usage has been come to an obvious reduction in many countries as a result of mainly lack of compliance to it due to parenteral route of the medication, short half-life, organ toxicity and its adverse effects⁷⁻⁹ which accounts for more than 67% of the mortality of β -thalassemia patients.¹⁰ Thus, researchers have been looking for a more proper drug with higher efficacy and compliance and lower complications. Deferasirox (Exjade®, ICL670); a tridentate can be orally absorbed and has a half-life of 11-19 hours which can be prescribed once daily.^{11,12}

Osveral® is a brand name for Deferasirox manufactured by Osvah, an Iranian Pharmaceutical Company. Osveral® received its marketing authorization through National Food and Drug Department of Iran Ministry of Health and is among the drugs reimbursed by national health insurance scheme. We aimed to compare the efficacy and safety of Deferasirox (Exjade®) versus Osveral® in transfusion dependent thalassemia major patients with evidence of transfusion induced iron overload.

Patients and Methods

We conducted a non-randomized clinical trial in which 69 patients with β -thalassemia major referring to Mofid Children's Hospital were enrolled. Eligible subjects received detailed explanations about the study and informed consent was obtained. For patients younger than 18 years of age, the informed consent was obtained from their parents or guardians. This study was conducted in concordance with the principles of the Declaration of Helsinki. Approval for the conduct of this study was obtained from the Research Ethics Committee and Institutional Review Board of Shahid Beheshti University of Medical Sciences. This trial has also been registered in International Clinical Trials Registry Platform (registration number: IRCT2015102524679N2). We included thalassemic patients older than 2 years who had received more than 10 times blood transfusion and had not compliance for taking Deferoxamine. The patients should have normal serum levels of creatinine, serum levels of liver transaminases less than 5 times the normal value, normal complete blood count and serum ferritin levels higher than 1000 ng/ml. Exclusion criteria comprised of patients with heart failure, positive for hepatitis B, C and HIV, presence of proteinuria, severe nausea/vomiting, skin rash or any other disease in which performing MRI is contraindicated. It was a non-randomized control since the decision on taking Exjade versus Osveral was mainly based on affordability of the medication by parents.

Primary outcome parameters were determining iron overload status of the patients; at baseline and 12 months after treatment with iron chelators, which was achieved by measuring the mean serum ferritin level and assessment of cardiac and liver iron content by MRI T2*. Secondary outcome parameters included determination

of the mean dose of the prescribed Deferasirox (Exjade®) and Osveral® and their adverse effects.

Participants received either Deferasirox (Exjade®) (Novartis CO., Stein, Switzerland) or Osveral® (Osvah Co., Tehran, Iran), whichever they could afford. The starting dose for either drug was 20 mg/kg/day which was reduced or increased by 5-10 mg/kg/day according to changes in serum ferritin levels; so that ranged between 10-40 mg/kg/day. Serum levels of ferritin were measured in three-month intervals. Mean serum ferritin levels, measured three times during the last 6 months before the start of the treatment was considered as the baseline value and was compared with post-treatment values checked every three months.

MRI was performed before and one year after starting the trial. In liver, relaxation times higher than 6.3 ms was considered as normal, 2.8-6.3 ms as mild, 1.4-2.8 ms as moderate and less than 1.4 ms as severe iron overload. In heart, MRI relaxation time higher than 20 ms was considered as normal, 15-20 ms as mild, 10-15 ms as moderate and less than 10 ms as severe iron overload. According to a previous study,¹³ MRI T2* is the most sensitive method for measuring cardiac and liver iron content. The dose of the drugs were tailored according to serum ferritin level for each patient. The probable adverse effects of Exjade® or Osveral® were registered in the patient's data sheet through history taking and physical examination in each visit. Nephrotoxicity was diagnosed if rise in creatinine on two consecutive visits was observed. Also if aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels were increased to ten times the normal, hepatotoxicity was suggested. The drugs were discontinued if nephrotoxicity or hepatotoxicity was occurred.

Statistical analysis was performed by Statistical Package for Social Sciences (SPSS) for Windows 16.0 (SPSS Inc., Chicago, IL, USA). To assess distribution of the continuous variables, Kolmogorov-Smirnov test was performed. Descriptive statistics were given by means and 95% confidence interval for normally distributed data. Categorical data were listed by absolute and relative frequencies. In analytical statistics, Nominal or ordinal variables were compared between groups by chi-square test and Fisher's exact test, depending on the expected cell counts of the corresponding crosstabs. In addition, unpaired Student *t*-test was used when the variables fulfilled the presumption of normal distribution, whereas the Mann-Whitney *U* test was used when the variables were not normally distributed. Paired *t*-test was applied to compare the values before and after the study. The results of the two-sided tests were considered significant if *p*-value was less than 0.05.

Results

69 patients affected by beta thalassemia major were enrolled into the study. Thirty patient were assigned to take Exjade® and 39 patients to take Osveral®. Mean age of the patients was 13.63 years (95% CI, 11.59-15.43 years). There was no difference between the two groups in terms of age. Forty two patients were male and twenty

seven were female ($P=0.53$).

Mean serum ferritin levels are shown in table 1. They showed no statistically significant difference between the two groups at the beginning, duration of the study (every three months) and end of the study. The mean dose of Exjade® and Osveral® during the study was 29.69 mg/kg/day and 25.87 mg/kg/d, respectively.

Changes in liver iron overload assessed by MRI T2* was not significant in Exjade® group during the study, but in Osveral® group the improvement (decrease in liver iron overload) was significant (0.99 ms in Exjade® group vs 1.16 ms in Osveral® group, $P=0.007$). In the group of patients who received Osveral®, the change in cardiac MRI T2* was not significant; however, in Exjade® group the improvement (decrease in cardiac iron overload) was significant (4.52 in Exjade group vs. 1.71 in Osveral group, $P<0.001$) (table 2).

Skin rash was seen in 7 (17.9%) patients in Exjade® group and 5 (16.7%) in Osveral® group ($p=0.88$). Increasing liver transaminase levels were seen in 5 (12.8%) in Exjade® group and 5 (16.7%) in Osveral® group ($p=0.653$). The rising of serum creatinine was significantly lower in Osveral® group in compared with Exjade® group (53.8% in Exjade® vs 26.7% in Osveral® group).

Increased protein to creatinine ratio (>0.6 mg/mg) was seen in two participants. One in Exjade® and one in Osveral® group.

Discussion

Transfusional iron-overload is a challenging issue in treatment of thalassemia patients who receive regular blood transfusions. It should be managed using chelating agents such as Deferoxamine (Desferal®), Deferiprone (Ferroprox®) and Deferasirox (Exjade®).¹⁴ Deferasirox which is an oral iron chelator has been shown to have similar efficacy and safety compared with Deferoxamine in patients with β -thalassemia in previous studies.¹⁵⁻¹⁷

Cappellini et. al in a longitudinal study indicated the efficacy and safety of Exjade® after 5 years follow-up.¹⁸ Alavi et. al have proven the efficacy of

Deferasirox (Exjade®), particularly in mild to moderate iron overload with 67% success rate in Iranian children at optimal doses of 30-40 mg/kg/day.¹⁹ Cassinerio and co-workers evaluated the efficacy of Exjade® in prevention and removing cardiac and liver iron and cardiac volume changes on 23 thalassemia patients using T2* cardiovascular magnetic resonance (CMR). They found that after 5 years of treatment, Exjade® significantly reduced myocardial and liver iron overload and prevented further iron deposition.¹¹

Molavi and co-workers conducted a clinical trial on 80 patients with thalassemia receiving Osveral®. They determined the efficacy of this agent by measurement of serum ferritin levels during a one-year period of treatment. In this study, decreasing trends in serum ferritin levels was observed; however, small increases were noted in the first three to four months of the treatment.²⁰ In a multicenter study on 407 patients with thalassemia, the researchers evaluated the efficacy and safety of Osveral® in Iranian patients. The results showed a promising profile of safety and efficacy of Osveral®.²¹

The results of the current study showed the efficacy of Osveral®, assessed by MRI T2 * of heart and liver was similar to that of Exjade®. Increased serum creatinine was the most serious complication in this study. Other complications such as skin rash, increased liver transaminase levels and high protein/creatinine ratio were not different between the two groups. Similarly, Eshghi and colleagues reported increase in serum creatinine as the most common complication of Osveral (24%). Cappellini and colleagues have also reported increase in serum creatinine level as the most common adverse effect of Exjade.²⁰ In current study this complication was statistically more observed in the exjade group ($P=0.029$).

Eshghi and co-workers reported elevated liver transaminase levels in 6% of participants who received Osveral;²¹ whereas, it was present in 14.5% of the participants in our study. Although their study included a high number of cases from nine centers, their study did not have any control group to compare the efficacy and

Table 1: Mean and standard deviation of serum ferritin levels in two groups of thalassmic patients receiving Exjade vs Osveral

| | Exjade® | Osveral® | P value |
|--------------------------------------------------------------|-----------|-----------|---------|
| Baseline ferritin, ng/ml | 1796±1040 | 1900±1007 | 0.68 |
| Ferritin level in the first three months after intervention | 1948±1006 | 2085±986 | 0.58 |
| Ferritin level in the second three months after intervention | 2020±1163 | 2097±922 | 0.77 |
| Ferritin level in the third three months after intervention | 2419±1192 | 2045±907 | 0.19 |
| Ferritin level, twelve months after intervention | 2072±680 | 1978±1058 | 0.81 |

Table 2: Liver and cardiac MRI T2* before and after intervention

| | Mean (95% CI), ms | P value |
|-----------------------------------------------------|---------------------|---------|
| Liver MRI-T2 * before intervention in Exjade group | 4.72 (3.76-5.38) | 0.377 |
| Liver MRI T2 * before intervention in Osveral group | 4.14 (3.54-5.30) | |
| Liver MRI T2 * after intervention in Exjade group | 6.29 (4.5-7.28) | 0.376 |
| Liver MRI T2 after intervention in Osveral group | 5.31 (4.31-6.31) | |
| Heart MRI T2 before intervention in Exjade group | 26.20 (23.56-28.7) | 0.014 |
| Heart MRI T2 before intervention in Osveral group | 21.41 (18.73-23.87) | |
| Heart MRI T2 after intervention in Exjade group | 30.42 (28.02-32.92) | <0.001 |
| HeartMRI T2 after intervention in Osveral group | 23.13 (20.52-25.83) | |

also the adverse effects.

Galanello et. al have also evaluated deferasirox safety in a phase II clinical trial in 2006 in 39 pediatric patients and have reported good tolerance, no toxicity, and no cases of mortality, but they reported four cases of severe adverse effect that included mild nausea and skin rash.²²

The current study indicated that dose of treatment was not different between two groups receiving exjade vs osveral. The ESCALATOR study and other studies^{23,24} have confirmed that the efficacy of deferasirox is dose-dependent and that dose adjustments should be closely observed in patients suffering from β -thalassemia for the utmost efficacy of the drug.

The strengths of the current study includes comparing the efficacy and safety of two drugs for iron clearance of the liver and heart by a standard method before and after treatment in a center specialized for thalassemia in Iran.

In conclusion, osveral, manufactured in Iran, is as efficient as exjade, manufactured in Switzerland for iron chelation and can be a good substitute for it in Iran, where the main drug is more expensive. We conclude that use of Osveral represents a cost-effective option for treatment of iron overload in Iranian patients with β -thalassemia and could be used as an alternative to Exjade in patients with low income.

Conflict of Interest: None declared.

References

- Vichinsky EP. Changing patterns of thalassemia worldwide. *Ann N Y Acad Sci.* 2005; 1054:18-24. doi: 10.1196/annals.1345.003. PubMed PMID: 16339647.
- Weatherall D, Clegg J. Inherited haemoglobin disorders: an increasing global health problem. *Bull World Health Organ.* 2001; 79(8):704-12. doi: 10.1590/S0042-96862001000800005. PubMed PMID: 11545326. PubMed Central PMCID: PMC2566499.
- Ghotbi N, Tsukatani T. Evaluation of the national health policy of thalassaemia screening in the Islamic Republic of Iran. *East Mediterr Health J.* 2005; 11(3):305-18.
- Welch J. Diagnosis and management of thalassaemia. *Pediatr Child Health.* 2015; 25(8):360-7. doi: 10.1016/j.paed.2015.03.001.
- Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR, Thalassaemia Clinical Research Network. Complications of β -thalassaemia major in North America. *Blood.* 2004; 104(1):34-9. doi: 10.1182/blood-2003-09-3167. PubMed PMID: 14988152.
- Rund D, Rachmilewitz E. β -Thalassemia. *N Engl J Med.* 2005; 353(11):1135-46. doi: 10.1056/NEJMra050436. PubMed PMID: 16162884.
- Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. *Br J Haematol.* 2004; 127(3):348-55. doi: 10.1111/j.1365-2141.2004.05202.x. PubMed PMID: 15491298.
- Molavi MA, Doozandeh H, Nazemi AM, Evazi R, Mansoori F. Comparison of therapeutic response and complications of oral osveral and injection desferal chelating Agent in patient with thalassemia major. *Asian J Med Pharm Res.* 2013; 3(3): 93-7.
- Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β -thalassaemia major: A prospective, single center, open-label study. *Pediatr Blood Cancer.* 2015; 62(9):1592-6. doi: 10.1002/pbc.25533. PubMed PMID: 25820920.
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *haematologica.* 2004; 89(10):1187-93. PubMed PMID: 15477202.
- Cassinerio E, Roghi A, Orofino N, Pedrotti P, Zanaboni L, Poggiali E, et al. A 5-year follow-up in deferasirox treatment: improvement of cardiac and hepatic iron overload and amelioration in cardiac function in thalassemia major patients. *Ann Hematol.* 2015; 94(6):939-45. doi: 10.1007/s00277-014-2291-x. PubMed PMID: 25563596.
- Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion dependent iron overload due to beta-thalassemia. *J Clin Pharmacol.* 2003; 43(6):565-72. doi: 10.1177/0091270003043006002. PubMed PMID: 12817519.
- Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi S, et al. Sensory neural hearing loss in β -thalassaemia major patients treated with deferoxamine. *Pediatr Hematol Oncol.* 2008; 25(6):502-8. doi: 10.1080/08880010802234911. PubMed PMID: 18728969.
- Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, et al. Deferasirox for managing iron overload in people with thalassaemia. *Cochrane Database Syst Rev.* 2012; (2):CD007476. doi: 10.1002/14651858.CD007476. PubMed PMID: 22336831.
- Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β -thalassaemia patients. *Transfusion.* 2013; 53(8):1722-9. doi: 10.1111/trf.12024. PubMed PMID: 23241074.
- Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. *haematologica.* 2006; 91(7):873-80. PubMed PMID: 16818273.
- Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Séchaud R, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a

- randomised, double-blind, placebo-controlled, dose-escalation trial. *The Lancet*. 2003; 361(9369):1597-602. doi: 10.1016/S0140-6736(03)13309-0. PubMed PMID: 12747879.
18. Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. *Blood*. 2011; 118(4):884-93. . doi: 10.1182/blood-2010-11-316646. PubMed PMID: 21628399.
 19. Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F. Efficacy and Safety of Deferasirox in β -Thalassemia Major Patients in Iran: A Prospective Study from a Single referral Center in Iran. *Pediatr Hematol Oncol*. 2014; 31(1):76-86. doi: 10.3109/08880018.2013.861046. PubMed PMID: 24383712.
 20. Molavi MA, Jomehpoor F, Nazemi Gheshmi A, Sajjadi HS. Assessment of Effectiveness and Side Effects of Osveral Chelator Drug in Major Thalassemia Patients with Iron Overload. *J Appl Environ Biol Sci*. 2012; 2(5):153-6.
 21. Eshghi P, Farahmandinia Z, Molavi M, Naderi M, Jafroodi M, Hoorfar H, et al. Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study. *Daru*. 2011; 19(3):240-8.
 22. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. *haematologica*. 2006; 91(10):1343-51.
 23. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron overloaded patients with beta-thalassemia: the ESCALATOR study. *Eur J Haematol*. 2009; 82(6):458-65. doi: 10.1111/j.1600-0609.2009.01228.x. PubMed PMID: 19187278.
 24. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β -thalassemia major. *Blood*. 2008; 111(2):583-7. doi: 10.1182/blood-2007-08-109306. PubMed PMID: 17951527.